Imunon (NASDAQ:IMNN) Given New $12.00 Price Target at HC Wainwright

Imunon (NASDAQ:IMNN) had its price objective cut by analysts at HC Wainwright from $14.00 to $12.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Trading Down 2.2 %

NASDAQ IMNN traded down $0.02 during trading on Monday, hitting $0.78. 147,288 shares of the company’s stock were exchanged, compared to its average volume of 982,085. The stock’s 50 day moving average price is $1.01 and its two-hundred day moving average price is $1.20. The company has a market cap of $46.97 million, a PE ratio of -0.41 and a beta of 2.14. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65.

Imunon (NASDAQ:IMNN) last released its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.04. Analysts forecast that Imunon will post -1.71 earnings per share for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.